Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of desoxycorticosterone. DOCP is a long-acting ester of desoxycorticosterone acetate (DOCA) which is recognized as having the same qualitative effects as the natural mineralocorticoid hormone aldosterone. It’s used as Percorten-V for replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. Percorten-V is only available in the U.S., Canada, Australia and recently, Denmark. Percorten was originally developed for the treatment of Addison's disease in humans but the demand for it decreased significantly once Florinef was available. Unaware that their product was being prescribed “off-label” for the treatment of canine Addison’s Disease and faced with a decreased demand for Percorten, the manufacturer *almost* discontinued production until the veterinary community rose up and voiced their distress. Field trials were run and the FDA approved the use of Percorten-V (the "v" is for veterinary). DOCP like other adrenocorticoid hormones is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin that result in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiologic effects seen after administration. The most important effect of DOCP is to increase the rate of renal tubular absorption of sodium. This effect is seen most intensely in the thick portion of the ascending limb of the loop of Henle. It also increases sodium absorption in the proximal convoluted tubule but this effect is less important in sodium retention. Chloride follows the sodium out of the renal tubule. Another important effect of DOCP is enhanced renal excretion of potassium. This effect is driven by the resorption of sodium that pulls potassium from the extracellular fluid into the renal tubules, thus promoting potassium excretion.

dl-α-tocopheryl phosphate has a growth acceleration effect on domestic fowl. Also was confirmed, that in all investigated animals dl-α-tocopheryl phosphate has an ability to being converted into vitamin E.

Sodium acetate C-11 (C-11 acetate) Injection is a radiopharmaceutical commonly used for clinical studies with positron emission tomography (PET). It is used as a PET radiotracer for imaging cancer cells via incorporation into intracellular phosphatidylcholine membrane microdomains in cancer cells. Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. C-11 acetate is taken up in proportion to fatty acid synthesis. It is also taken up proportionally to myocardial blood flow, and therefore myocardial oxygen consumption. In rodents, there is clearance from all organs except the pancreas within one hour. Tumor uptake was clearly visible in 30 minutes. In humans, more than 80% of tracer is cleared from normal tissues within 20 minutes.It is taken up in cancer within the prostate and prostate cancer metastases, however, it has been reported that increased uptake can be seen in hyperplastic and benign prostate tissues. No urinary excretion is seen. No toxic effects have been demonstrated. The ongoing clinical trial NCT01530269 is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments of prostate cancer.

Isobronyl acetate (an isomer of bornyl acetate) is a component of many essential oils, which was observed to be inhibitory to microorganisms. It was also shown to have sedative effect on mice after inhalation. Isobronyl acetate is mainly used in cosmetics as a flavor and fragrance agent.